Why the study?
Does dual therapy with an angiotensin-converting enzyme inhibitor and angiotensin receptor blocker reduce the progression of renal disease in patients with nephropathy?
Does dual therapy with an angiotensin-converting enzyme inhibitor and angiotensin receptor blocker reduce the progression of renal disease in patients with nephropathy?
Answers are grounded in this paper and cite their sources.
This review highlights that despite improving surrogate markers like blood pressure and albuminuria, dual RAS therapy increases renal risk in patients with nephropathy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2010) conducted a review in Kidney disease / Nephropathy. Dual-agent RAS therapy (ACE inhibitor and ARB) vs. Single-agent RAS therapy was evaluated on Renal risk / progression of renal disease.
Synapse has enriched 10 related papers. Consider them for comparative context: